Disease-modifying drugs for multiple sclerosis: a rapid and systematic review.

Disease-modifying drugs for multiple sclerosis: a rapid and systematic review.

Bibliographic Details
Main Authors:	Clegg, Bryant, Milne
Format:	Article
Language:	English
Published:	NIHR Journals Library 2000-01-01
Series:	Health Technology Assessment
Online Access:	https://doi.org/10.3310/hta4090

Similar Items

Disease modifying therapies in multiple sclerosis: cost-effectiveness systematic review
by: Cristian Eduardo Navarro, et al.
Published: (2020-03-01)

Implantable cardioverter defibrillators: arrhythmias. A rapid and systematic review.
by: Parkes, et al.
Published: (2000-01-01)

Treatments for fatigue in multiple sclerosis: a rapid and systematic review.
by: Brañas, et al.
Published: (2000-01-01)

Cost-Effectiveness of Multiple Sclerosis Disease-Modifying Therapies: A Systematic Review of the Literature
by: David Yamamoto, et al.
Published: (2012-01-01)

The role of specialist nurses in multiple sclerosis: a rapid and systematic review
by: S. De Broe, et al.
Published: (2001-01-01)

Disease-modifying agents in multiple sclerosis
by: Coyle P
Published: (2009-01-01)

Monogenic Diseases Masquerading as Multiple Sclerosis: A Systematic Review
by: Marino, Meghan J.
Published: (2011)

Patients’ satisfaction with and views about treatment with disease-modifying drugs in multiple sclerosis
by: Caroline Vieira Spessotto, et al.
Published: (2016-08-01)

When to Initiate Disease-Modifying Drugs for Relapsing Remitting Multiple Sclerosis in Adults?
by: Mona Alkhawajah, et al.
Published: (2011-01-01)

Multiple Sclerosis, Disease-Modifying Therapies and COVID-19: A Systematic Review on Immune Response and Vaccination Recommendations
by: Verónica Cabreira, et al.
Published: (2021-07-01)

Real-world adherence to, and persistence with, once- and twice-daily oral disease-modifying drugs in patients with multiple sclerosis: a systematic review and meta-analysis
by: Jacqueline A. Nicholas, et al.
Published: (2020-07-01)

Recommendations for switching patients with highly active multiple sclerosis from other disease modifying drugs for multiple sclerosis to cladribine tablets
by: N. A. Totolyan, et al.
Published: (2020-10-01)

Clinicial and cost-effectiveness of donepezil, rivastigmine and galantamine for Alzheimer's disease: a rapid and systematic review
by: Clegg, A., et al.
Published: (2001)

Clinical and cost-effectiveness of donepezil, rivastigmine and galantamine for Alzheimer's disease: a rapid and systematic review
by: J. Bryant, et al.
Published: (2001-01-01)

The Effect of Disease Modifying Therapies on Disease Progression in Patients with Relapsing-Remitting Multiple Sclerosis: A Systematic Review and Meta-Analysis.
by: Georgios Tsivgoulis, et al.
Published: (2015-01-01)

Systematic imaging review: Multiple Sclerosis
by: Aparna Katdare, et al.
Published: (2015-01-01)

Reliability in long-term clinical studies of disease-modifying therapies for relapsing-remitting multiple sclerosis: A systematic review.
by: Rosa C Lucchetta, et al.
Published: (2020-01-01)

Disease-Modifying Drugs and Family Planning in People with Multiple Sclerosis: A Consensus Narrative Review from the Gulf Region
by: Raed Alroughani, et al.
Published: (2020-06-01)

Multiple sclerosis and pregnancy. Impact of multiple sclerosis disease-modifying therapy on the health of newborns
by: T. I. Yakushina
Published: (2021-02-01)

Pharmacogenomics of Multiple Sclerosis: A Systematic Review
by: Keli Hočevar, et al.
Published: (2019-02-01)

Women’s Experiences of Managing Relapsing-Remitting Multiple Sclerosis with Disease Modifying Drugs: A Dissertation
by: Terrill, Eileen F.
Published: (2007)

The effect of disease modifying therapies on brain atrophy in patients with relapsing-remitting multiple sclerosis: a systematic review and meta-analysis.
by: Georgios Tsivgoulis, et al.
Published: (2015-01-01)

The Effect of Disease Modifying Therapies on Disability Progression in Multiple Sclerosis: A Systematic Overview of Meta-Analyses
by: Suzi B. Claflin, et al.
Published: (2019-01-01)

Safety of Newer Disease Modifying Therapies in Multiple Sclerosis
by: Georges Jalkh, et al.
Published: (2021-12-01)

The Effects of Multiple Sclerosis and Disease Modifying Therapy on Pregnancy
by: Tarneer Kaur Johal
Published: (2017-12-01)

Adherence to disease-modifying therapies in patients with multiple sclerosis
by: Kołtuniuk A, et al.
Published: (2018-08-01)

Predicting response to disease modifying treatment in multiple sclerosis
by: Gafson, Arie R.
Published: (2017)

Patient preferences for disease-modifying drugs in multiple sclerosis therapy: a choice-based conjoint analysis
by: Kathrin S. Utz, et al.
Published: (2014-11-01)

Adherence to Disease Modifying Drugs among Patients with Multiple Sclerosis in Germany: A Retrospective Cohort Study.
by: Kerstin Hansen, et al.
Published: (2015-01-01)

The Effect of Disease-Modifying Drugs on Brain Atrophy in Relapsing-Remitting Multiple Sclerosis: A Meta-Analysis.
by: Pierre Branger, et al.
Published: (2016-01-01)

Mitochondrial Dysfunction in Multiple Sclerosis: A Systematic Review
by: Alia Saberi, et al.
Published: (2019-02-01)

Metabolomic Biomarkers of Multiple Sclerosis: A Systematic Review
by: Lachlan Porter, et al.
Published: (2020-12-01)

Cost of Illness of Multiple Sclerosis - A Systematic Review.
by: Olivia Ernstsson, et al.
Published: (2016-01-01)

Update on riboflavin and multiple sclerosis: a systematic review
by: Mahshid Naghashpour, et al.
Published: (2017-09-01)

The utility of Magnetoencephalography in multiple sclerosis – A systematic review
by: H. Khan, et al.
Published: (2021-01-01)

Post-natalizumab disease reactivation in multiple sclerosis: systematic review and meta-analysis
by: Luca Prosperini, et al.
Published: (2019-03-01)

DOES THE TYPE OF DISEASE-MODIFYING DRUGS IMPACT ON THE QUALITY OF LIFE IN PATIENTS WITH RELAPSING-REMITTING MULTIPLE SCLEROSIS?
by: Amirreza NASERI, et al.
Published: (2020-09-01)

Disease-modifying drug initiation patterns in commercially insured multiple sclerosis patients: a retrospective cohort study
by: Kassed Cheryl A, et al.
Published: (2011-10-01)

Approved and Emerging Disease Modifying Therapies on Neurodegeneration in Multiple Sclerosis
by: Madeline Bross, et al.
Published: (2020-06-01)

Adherence to disease-modifying treatments in patients with multiple sclerosis in Spain
by: Morillo Verdugo R, et al.
Published: (2019-02-01)